The US has approved India’s Lupin Ltd’s generic version of Pfizer nerve pain drug treatment, confirms India’s Lupin Ltd.
Yes, the news of receiving an approval from the United States Food and Drug Administration (USFDA) has recently come from India's Lupin Ltd, which said that the company has won the U. S. approval to market generic version of Pfizer Inc's big-selling nerve pain treatment called Lyrica or pregabalin.
A spokesman for Lupin confirms still sometime to the launch of its version of the treatment. He said that the drug Lyrica has contributed approx $1.8 billion to the U. S. sales for the last year ended in March, revealed data from IMS Health Inc.
Soon the US market will be facilitated with generic version of Lyrica (Pregabalin) capsules with the help of which, medical professionals will be able to treat the acute pain that occurs in the nerves due to diabetes, herpes and fibromyalgia.
Till now, many generic drugs have been launched in US markets by an Indian company, Dr. Reddys, has already launched two generic drugs i. e. generic version of Roche’s anti-osteoporosis drug and the second one for acidity and heartburn.
Lupin Ltd’s subsidiary, Lupin Pharmaceuticals Inc. will be supplying all the doses i. e. 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg of the Pregabalin Capsules in the United States.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki